https://www.selleckchem.com/products/cay10444.html
F with greater specificity and improved prognostic accuracy than existing prognostic markers. Serum clusterin is a potential biomarker for HBV-ACLF which can be used to assess clinical severity and the short-term prognosis of patients with this disease and may help clinicians identify HBV-ACLF with greater specificity and improved prognostic accuracy than existing prognostic markers. This study is aimed at identifying genetic and epigenetic crosstalk molecules and their target drugs involved in the interaction between neural stem/proge
Like
Comment
Share
